102391-98-0 Usage
Description
(4-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE is a chemical compound that belongs to the class of piperazine derivatives. It is a synthetic compound that contains a piperazine ring with a fluorinated phenyl group and a methanone group attached to it. (4-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE has potential applications in medicinal chemistry and drug development, as piperazine derivatives are known for their diverse pharmacological activities, including as antipsychotic, anxiolytic, and antidepressant agents. The specific properties and biological activities of (4-fluoro-phenyl)-piperazin-1-yl-methanone have not been extensively studied, but its structure suggests that it may have potential as a pharmacologically active compound for further research and development.
Uses
Used in Pharmaceutical Industry:
(4-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE is used as a potential active pharmaceutical ingredient for the development of new drugs due to its diverse pharmacological activities as a piperazine derivative. Its potential applications include the treatment of psychiatric disorders such as schizophrenia, anxiety, and depression, as well as other conditions that may benefit from its pharmacological properties.
Used in Medicinal Chemistry Research:
(4-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE is used as a research compound in medicinal chemistry to explore its specific properties and biological activities. Further studies are needed to understand its potential as a pharmacologically active compound and to identify its mechanism of action, which could lead to the development of novel therapeutic agents.
Note: Since the provided materials do not specify any particular application or industry for (4-FLUORO-PHENYL)-PIPERAZIN-1-YL-METHANONE, the uses listed above are based on the general potential of piperazine derivatives in the pharmaceutical and medicinal chemistry fields. Further research and development are required to determine the specific applications and industries where this compound can be effectively utilized.
Check Digit Verification of cas no
The CAS Registry Mumber 102391-98-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,3,9 and 1 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 102391-98:
(8*1)+(7*0)+(6*2)+(5*3)+(4*9)+(3*1)+(2*9)+(1*8)=100
100 % 10 = 0
So 102391-98-0 is a valid CAS Registry Number.
102391-98-0Relevant articles and documents
Comprehensive evaluation of biological effects of pentathiepins on various human cancer cell lines and insights into their mode of action
Wolff, Lisa,Bandaru, Siva Sankar Murthy,Eger, Elias,Lam, Hoai-Nhi,Napierkowski, Martin,Baecker, Daniel,Schulzke, Carola,Bednarski, Patrick J.
, (2021)
Pentathiepins are polysulfur-containing compounds that exert antiproliferative and cytotoxic activity in cancer cells, induce oxidative stress and apoptosis, and inhibit glutathione peroxidase (GPx1). This renders them promising candidates for anticancer
Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms
Mancuso, Francesca,Di Fiore, Anna,De Luca, Laura,Angeli, Andrea,Monti, Simona M.,De Simone, Giuseppina,Supuran, Claudiu T.,Gitto, Rosaria
supporting information, p. 1000 - 1005 (2020/03/23)
We report the synthesis and biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeu
Discovery of novel Bcr-AblT315I inhibitors with flexible linker. Part 1: Confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety
Pan, Xiaoyan,Liang, Liyuan,Sun, Ying,Si, Ru,Zhang, Qingqing,Wang, Jin,Fu, Jia,Zhang, Junjie,Zhang, Jie
, p. 232 - 242 (2019/06/14)
As a continuation to our research, a series of novel Bcr-Abl inhibitors incorporated with 6-phenyl-1H-indazol-3-amine as hinge binding moiety (HBM) were developed based on confirmation analysis. Biological results indicated that these compounds exhibited an enhanced inhibition against Bcr-AblWT and Bcr-AblT315I in kinases assays, along with improved anti-proliferative activities in K562 cell assays. In particular, compound Y9 displayed comparable potency with that of imatinib. It potently inhibited Bcr-AblWT and Bcr-AblT315I kinases with IC50 of 0.043 μM and 0.17 μM, respectively. Furthermore, compound Y9 inhibited the proliferation of K562 and K562R cells with IC50 of 1.65 μM and 5.42 μM, respectively. Therefore, 6-phenyl-1H-indazol-3amine as HBM, combined with flexible linker, is a successful strategy contribute to research on T315I mutant resistance, and compound Y9 could be served as a starting point for further optimization.
